TY - JOUR
T1 - Variation over time in the association between polypharmacy and mortality in the older population
AU - Richardson, Kathryn
AU - Ananou, Alexandrine
AU - Lafortune, Louise
AU - Brayne, Carol
AU - Matthews, Fiona E.
N1 - Acknowledgements: The Cognitive Function and Ageing Study (CFAS) is funded by the Medical Research Council (MRC), UK. FM is funded by the UK Medical Research Council (U.1052.00.0013). We are grateful to the respondents, their families and their family practices for all their help in the study. The MRC CFAS is a member study of the Cambridgeshire and Peterborough Collaboration for Leadership in Applied Health Research & Care (CLAHRC). The funders had no role in the preparation of this article. The authors have no conflicts of interests relevant to the content of this study.
PY - 2011/7
Y1 - 2011/7
N2 - Background: In the older population, multimorbidity is common and best practice may invite the prescription of multiple medications. Objective: To examine the association between polypharmacy, defined as the concurrent use of five or more prescription or nonprescription medications, and mortality in 12 423 participants aged <65 years representative of the older population of England and Wales. Methods: Data on self-reportedmedication use, disability and health conditions were collected at baseline in 19913. The cohort was followed for up to 18 years with full mortality notification. Cox proportional hazards regression adjusted for age, baseline institutionalization, smoking, disability and health conditions was used to investigate polypharmacy and mortality, stratified by sex. Various methods for modelling the time-varying effect of polypharmacy are presented. Results: A strong independent association between polypharmacy and mortality existed in the short-term (first 2 years) for bothmen andwomen. This association remained, although attenuated, in the medium-long term (218 years of followup) for women, but became non-significant in the longer term for men. Conclusions: It remains unclear whether polypharmacy is a marker for poor health or is an independent risk factor for mortality. However, polypharmacy strongly predicts adverse outcomes, and multiple medication use should therefore be carefully monitored in the older population.
AB - Background: In the older population, multimorbidity is common and best practice may invite the prescription of multiple medications. Objective: To examine the association between polypharmacy, defined as the concurrent use of five or more prescription or nonprescription medications, and mortality in 12 423 participants aged <65 years representative of the older population of England and Wales. Methods: Data on self-reportedmedication use, disability and health conditions were collected at baseline in 19913. The cohort was followed for up to 18 years with full mortality notification. Cox proportional hazards regression adjusted for age, baseline institutionalization, smoking, disability and health conditions was used to investigate polypharmacy and mortality, stratified by sex. Various methods for modelling the time-varying effect of polypharmacy are presented. Results: A strong independent association between polypharmacy and mortality existed in the short-term (first 2 years) for bothmen andwomen. This association remained, although attenuated, in the medium-long term (218 years of followup) for women, but became non-significant in the longer term for men. Conclusions: It remains unclear whether polypharmacy is a marker for poor health or is an independent risk factor for mortality. However, polypharmacy strongly predicts adverse outcomes, and multiple medication use should therefore be carefully monitored in the older population.
KW - Drug-utilisation
KW - Elderly
KW - Mortality
KW - Prescribing
UR - https://www.scopus.com/pages/publications/79960018797
U2 - 10.2165/11592000-000000000-00000
DO - 10.2165/11592000-000000000-00000
M3 - Article
C2 - 21721599
AN - SCOPUS:79960018797
SN - 1170-229X
VL - 28
SP - 547
EP - 560
JO - Drugs and Aging
JF - Drugs and Aging
IS - 7
ER -